Tag Archives: Medical Technology

DAMO Academy and the World Health Organization Collaborate to Push Medical AI Boundaries for Developing Countries

Alibaba Group’s research institute, DAMO Academy, has joined forces with the World Health Organisation (WHO) Collaborating Center on Digital Health in a landmark partnership to advance medical AI innovations and expand accessibility in developing countries. This collaboration signifies a significant step towards leveraging cutting-edge AI technology to improve global healthcare outcomes.

Dr. Le Lu head of DAMO Academys medical AI speaks at the AI for Good global summit
Source: Alibaba Cloud

The WHO Collaborating Center on Digital Health, the first of its kind in the Western Pacific region, plays a pivotal role in supporting WHO initiatives. It spearheads digital health information exchange, scientific research, and international standard development, while also providing technical training to member countries.

This strategic partnership, officially launched at the UN’s AI for Good Global Summit in Geneva, unites the strengths of both entities. DAMO Academy and the WHO Collaborating Center will collaborate on research and provide expert guidance in the fields of digital health, AI, and industrial development, ultimately supporting organizations like the WHO and the International Telecommunication Union.

An Inherently Interdisciplinary Collaboration

Recognizing the inherently interdisciplinary nature of AI and digital health, the partnership also focuses on joint training initiatives. These programs will encompass medicine, engineering, digital health, AI, industrial development, and other relevant fields. The goal is to cultivate a new generation of professionals equipped with the comprehensive skillset necessary to advance digital healthcare solutions.

Furthermore, the WHO Collaborating Center will leverage its resources to actively promote DAMO Academy’s medical AI solutions in developing countries. This strategic move strengthens international outreach for digital health initiatives, ultimately fostering health and wellness through technological advancements.

“Through this partnership with the WHO Collaborating Center on Digital Health, DAMO Academy embarks on a mission to democratize access to medical AI for those in need,” said Le Lu, Head of DAMO Academy’s medical AI team. “By working together, we aim to leverage advancements in medical AI development and digital health accessibility to improve healthcare for underserved communities.”

“This collaboration signifies not just a shared vision but a tangible commitment to harnessing the power of digital innovations to cultivate global health and wellness,” echoed Shan Xu, Head of the WHO Collaborating Centre on Digital Health. “By pooling our expertise and leveraging cutting-edge AI technology, we are poised to drive a transformative shift in digital health, particularly for developing countries.”

Pioneering Multi-Cancer Early Detection with AI

DAMO Academy’s medical AI team is at the forefront of exploring cost-effective and efficient methods for multi-cancer screening using AI technology. This ongoing research, conducted in collaboration with leading global medical institutions, has yielded significant progress. Their AI model demonstrates exceptional promise in detecting seven common cancers, including pancreatic, oesophagal, lung, breast, liver, gastric, and colorectal, all from a single CT scan.

Doctor at a hospital in Lishui city of Chinas Zhejiang province examines a CT scan
Source: Alibaba Cloud

This achievement is particularly noteworthy in the case of pancreatic cancer, a notoriously difficult-to-detect disease with a poor prognosis when identified at later stages. A large-scale real-world pancreatic cancer detection study, published in Nature Medicine by DAMO Academy and a consortium of over 10 medical institutions, revealed an impressive sensitivity of 92.9% and a specificity of 99.9% achieved by their AI model. This technology is already being implemented in two hospitals within China’s Zhejiang province as part of Alibaba’s philanthropic program, demonstrating its real-world potential.

The DAMO Academy and WHO Collaborating Center on Digital Health partnership represents a significant milestone in the global healthcare landscape. By combining expertise and resources, this collaboration holds immense promise for expanding access to advanced medical AI solutions in developing countries. This, in turn, has the potential to revolutionize healthcare delivery and improve health outcomes for millions around the world.

New Weapon in the Fight Against Pneumonia: Vaxneuvance™ Expands Protection in Malaysia

A new vaccine called Vaxneuvance™, developed by MSD, has arrived in Malaysia. This next-generation vaccine offers broader protection against this serious illness compared to previous options.

VAXNEUVANCE 1

How does it work? Vaxneuvance™ is a 15-valent conjugate vaccine. This means it contains components (polysaccharides) from 15 different strains of the bacteria Streptococcus pneumooniae attached to a protein carrier. When your body encounters the vaccine, your immune system learns to recognize these polysaccharides and create antibodies. These antibodies can then fight off actual infections caused by these specific strains of the bacteria in the future.

What strains does it protect against? Vaxneuvance™ specifically targets the following 15 pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F. These strains are also responsible for a significant portion of pneumococcal disease cases in Malaysia.

Who can get vaccinated? The good news is that Vaxneuvance™ is approved for children (as young as 6 weeks old) and adults.

Doctors are optimistic. Medical professionals are excited about the broader protection offered by Vaxneuvance™. Prof Datuk Dr. Zulkifli Ismail, a consultant paediatrician, says the new vaccine “addresses the evolving landscape of pneumococcal disease in Malaysia.” This means it can potentially combat strains that may be becoming more prevalent. In addition, he notes that the vaccine provides “a strong immune response to serotypes that pose substantial risk to infants and children.”.

Further, Assoc. Professor Petrick Periyamsamy, an Infectious Disease Specialist, highlights that the new vaccine addresses the adult population by addressing serotype 3 of Streptococcus pnuemoniae. This serotype is most common in the adult population and poses a serious health risk among adults.

pexels olly 3807629
Photo by Andrea Piacquadio

When and where can I get vaccinated? Vaxneuvance™ is now available at clinics and hospitals across Malaysia. Talk to your doctor to see if it’s right for you or your child.

Key points to remember:

  • Vaxneuvance™ is a 15-valent pneumococcal conjugate vaccine.
  • It protects against 15 specific strains of Streptococcus pneumoniae bacteria.
  • The vaccine has been shown to be safe and effective in clinical trials.
  • Talk to your doctor to see if Vaxneuvance™ is right for you or your child.

This new vaccine represents a significant step forward in protecting Malaysians from pneumococcal disease. By offering broader coverage, Vaxneuvance™ has the potential to significantly reduce the disease burden and its impact on individuals, families, and communities.

Bringing Intelligence to Medical Devices and Machines

Artificial intelligence (AI) is the science and engineering of creating machines or computer programs that can sense, reason, act, and adapt to come up with solutions for problems. As this definition shows, AI in itself is not a solution but rather a set of methods from which solutions can be developed.

Amongst the benefits of AI is its ability to imitate human cognitive behavior by analyzing data and its surroundings, solving or anticipating problems and self-learning to adapt to a variety of tasks.

Globally, healthcare systems are facing various challenges. This includes an ever-increasing aging population[1], escalating healthcare costs, operational inefficiencies, staff shortage, value-based reimbursements, higher percentage of deaths accounting to chronic illness, as well as an annual wastage of up to $750 billion on healthcare as seen in the United States alone. Against the background of these challenges, healthcare is also undergoing rapid digitalization.

For example, over the past decade, there has been an increase in growth of computational power, while the cost of data storage has dropped dramatically. As a result, the amount and quality of stored digital medical data has increased tremendously. However, there is a growing concern in healthcare that only a fraction of this data is being used to improve the quality and efficiency of care. The growth rate and diversity of medical data has far outpaced our ability to analyze it.

Recognizing this, Philips has developed intelligent solutions using these data and information on hand to help healthcare providers achieve improved health outcomes at a lower cost, while providing better staff and patient experience.

Philips Redesigning Medical Technology for Better

Philips offers a broad spectrum of solutions that spans the health continuum, from healthy living and prevention to diagnosis, treatment and home care; especially supported by its deep understanding in clinical needs, workflows, and regulations, as well as departmental and hospital workflows.

Spending approximately EUR 1.8 billion annually on R&D, innovation[2] is core to Philips’ growth strategy in health technology. In recent years, Philips has significantly improved its research in software and data science and today, almost one in every two of Philips’ R&D professionals focuses on the field of health technology.

On top of working closely with clinical partners across the globe – healthcare providers, academia, and hospital networks, Philips is among the top 5 healthcare IT companies with approximately EUR 3 billion in healthcare IT-related sales and has successfully developed the Philips HealthSuite Platforms, a digital framework that connects consumers, patients and healthcare providers in a cloud-based health ecosystem of devices, apps and tools.

Philips IntelliSpace Discovery offers an integrated AI solution that enables the entire process of generating new AI applications, providing data integration, training and deployment in the research setting.

Recognizing that public trust is paramount and understanding that health data is among the most sensitive types of personal data, Philips takes the growing risk of cybersecurity threats to its products very seriously. Security plans encompass people, processes and technology, with the goal of ensuring the confidentiality, integrity and availability of critical data and the systems that house that data.

How AI Can Help

Over the next decade, smart systems will be able to aggregate information from multiple sources that currently remain trapped in silos. For example, each individual patient’s data will be pulled together from the systems that are used in his/her GP surgery, hospital or specialist center, such as different Electronic Medical Records, diagnostic and monitoring solutions.

Today, slowly but surely, ASEAN countries are adopting AI and its elements to ensure systematic and efficient workflow within the healthcare industries.

Here is a quick look on how Philips is applying AI to address the challenges within healthcare industry:

  • Clinical informatics & decision supportPhilips IntelliSpace Portal offers an advanced visual analysis and quantification platform that uses machine learning to learn about the clinician’s workflow. It then automatically configures the system to apply the appropriate processing to specific types of studies to speed up their analysis.
  • Acute care – Philips IntelliVue Guardian System with Early Warning Scoring (EWS) aids in identifying subtle signs of deterioration in a general floor patient’s condition at the point of care. IntelliVue Guardian automated EWS helps to reduce ICU transfers and readmissions, and adverse events.
  • Home care – Philips CareSage, a predictive analytics technology that helps prevent avoidable hospital admissions and emergency room visits among the frail and elderly and DreamMapper, a mobile app that allows people with sleep apnea to track their therapy progress so they can take an active role in their therapy. It is designed to quickly correlate data on therapy usage, mask fit and apnea hypopnea index (AHI) readings to help improve treatment success.

[1] www.nia.nih.gov/research/publication/global-health-and-aging/preface. Published October 2011. Updated January 22, 2015. Accessed August 1, 2015.

[2]https://www.philips.com/a-w/about/news/archive/standard/news/press/2018/20181108-philips-provides-update-on-performance-and-value-creation-journey-at-capital-markets-day-in-amsterdam.html